ArticleAntibiotics (Basel, Switzerland)2021
Determination of a Tentative Epidemiological Cut-Off Value (ECOFF) for Dalbavancin and
Article in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Proactive Therapeutic Drug Monitoring of Dalbavancin in the Long-Term Treatment of Chronic Infections: A Narrative Review.Antibiotics (Basel, Switzerland) · 2026Review
- Enteric Pathogens in Wild Boars Across the European Union: Prevalence and Antimicrobial Resistance Within a One Health Framework.Antibiotics (Basel, Switzerland) · 2025Review
- Therapeutic Drug Monitoring Versus Fixed-Interval Dosing of Dalbavancin in Implant-Associated Spinal Infections: Grand Round/A Case Study.Therapeutic drug monitoring · 2025Article
- Antimicrobial Susceptibility Profiles of CommensalAntibiotics (Basel, Switzerland) · 2025Article
- Proactive Therapeutic Drug MONiToring to Guide Suppressive Antibiotic Therapy with DALBAvaNcin ( > 12 weeks) in Osteoarticular Infections (MONTALBANO).Journal of bone and joint infection · 2025Article
- Profiling Antibiotic Susceptibility among DistinctAntibiotics (Basel, Switzerland) · 2023Article
- Antimicrobial Susceptibility Testing for Enterococci.Journal of clinical microbiology · 2022Review
- Editorial for the Special Issue: "Antibiotic Use in Clinical Infection: How to Reinvent Old Molecules and How to Squeeze out New Ones".Antibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Dalbavancin is a lipoglycopeptide antibiotic that shows potent activity against Gram-positive bacteria. It circumvents
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.